Melatonin and IL-25 modulate apoptosis and angiogenesis mediators in metastatic (CF-41) and non-metastatic (CMT-U229) canine mammary tumour cells

G. B. Gelaleti, Thaiz Ferraz Borin, L. B. Maschio-Signorini, M. G. Moschetta, E. Hellmén, A. M. Viloria-Petit, D. A.P.C. Zuccari

Research output: Contribution to journalArticle

4 Scopus citations


Background: Melatonin has oncostatic actions and IL-25 is active in inflammatory processes that induce apoptosis in tumor cells. Aim: The aim of this study was to evaluate melatonin and IL-25 in metastatic (CF-41) and non-metastatic (CMT-U229) canine mammary tumor cells cultured as monolayers and tridimensional structures. Materials and Methods: The cells were treated with melatonin, IL-25 and IL-17B silencing gene and performed cell viability, gene and protein expression of caspase-3 and VEGFA (Vascular endothelial growth factor A) and an apoptosis membrane protein array. Results: Treatment with 1 mM of melatonin reduced cell viability of both tumor cell lines, all treatments alone and combined significantly increased caspase-3 cleaved and proteins involved in the apoptotic pathway and reduced pro-angiogenic VEGFA, confirming the effectiveness of these potential promising treatments. Conclusion: This is the first study evaluating the potential use of these strategies in CF-41 and CMT-U229 cell lines and together encourages subsequent in vitro and in vivo studies for further exploration of clinical applications.

Original languageEnglish (US)
Pages (from-to)1572-1584
Number of pages13
JournalVeterinary and Comparative Oncology
Issue number4
Publication statusPublished - Dec 1 2017



  • angiogenesis
  • apoptosis
  • canine
  • interleukin-25
  • mammary tumour cells
  • melatonin

ASJC Scopus subject areas

  • veterinary(all)

Cite this